FDA likes Exelixis drug for thyroid cancer; Ireland takes positive outlook on patent cliff; Insider trading scheme costs noted scientist;

@FiercePharma: Ranbaxy stops making generic Lipitor as news of 2nd recall surfaces. Story | Follow @FiercePharma

> The FDA has approved Cometriq from Exelixis ($EXEL) for treating progressive, metastatic medullary thyroid cancer. Release

> The FDA approved a new generic drug made by Mylan ($MYL) for urinary disorders, the company said Thursday. Item

> After testing the water, the family that owns New Zealand generic drug company Douglas Pharmaceuticals, decides not to sell. Story

> Contract manufacturer AMRI ($AMRI) is closing a plant in Bothell, WA, that employs 24. Item

> A report suggests that the patent cliff problems affecting Big Pharma will not hurt Ireland, where many of them operate, as much as first believed. Item

 @FierceMedDev: eBay co-founder invests heavily in India's medtech industry. Item | Follow @FierceMedDev

@MarkHFierce: Indictments filed in a long-standing med device insider trading case. An ex Angels ball player is involved. More | Follow @MarkHFierce

 @DamianFierce: With St. Jude's $1B stock repurchase, the company says the future will be stable. Do investors agree? Story | Follow @DamianFierce

> Stryker commits to $30M R&D expansion in Ireland. Report

> Boston Scientific aims for FDA approval with absorbable stent trial. News

> FDA says it's already speeding up device approvals. Article

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Study: Genomics, outsourcing fuel double-digit growth in bioinformatics. Report | Follow @FierceBiotech

 @JohnCFierce: BioCryst ends a very bad, disastrous, no good of any kind of month by terminating merger pact. News | Follow @JohnCFierce

 @RyanMFierce: Sounds like adult blood could best skin cells as source for stem cells. We'll see. BBC report. More | Follow @RyanMFierce

> Big Pharma backers fuel $17M first round for developer of brain-penetrating protein drugs. Article

> Exelixis grabs first FDA nod for blockbuster hopeful against thyroid cancer. Story

And Finally... Sid Gilman, a noted neurologist at the University of Michigan who is linked to the same insider trading case that has swept up some drug company executives, has resigned from his university position. Story
 

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.